ondansetron has been researched along with Vaginal Neoplasms in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Vaginal Neoplasms: Tumors or cancer of the VAGINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare rates of complete response (no emesis, retching, or rescue antiemetics) in the late phase (days 4-7 post-chemotherapy) of cycle 1 between transdermal granisetron and oral ondansetron in cervical, endometrial, or vaginal cancer survivors undergoing chemoradiation at The University of Texas MD Anderson Cancer Center and LBJ Hospital in Houston, TX." | 5.41 | A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. ( Armbruster, SD; Coleman, RL; Eifel, PJ; Fellman, BM; Frumovitz, M; Jhingran, A; Klopp, AH; Ramondetta, LM, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armbruster, SD | 1 |
| Fellman, BM | 1 |
| Jhingran, A | 1 |
| Eifel, PJ | 1 |
| Klopp, AH | 1 |
| Coleman, RL | 1 |
| Ramondetta, LM | 1 |
| Frumovitz, M | 1 |
1 trial available for ondansetron and Vaginal Neoplasms
| Article | Year |
|---|---|
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Agents; Cancer Survivors; Endometrial | 2021 |